Paracetamol β-D-Glucoside: Prodrug Design, Kinetics, and Regulatory Stability Assessment

Many medicines do not dissolve well in water, which can limit how quickly and effectively they work. One proven way to improve this is to attach a natural sugar molecule to the drug. In this study, we investigate paracetamol β-D-glucoside (C₁₄H₁₉NO₇), a modified form of paracetamol in which glucose is chemically linked to the drug through a β-glycosidic bond. This simple molecular change increases water solubility by 6–8 times compared to regular paracetamol, allowing faster dissolution and more flexible liquid formulations. The sugar–drug link is stable under normal body conditions but breaks apart under specific environments. At neutral pH (similar to blood), the compound remains highly stable, with a half-life exceeding 1000 hours at 25 ℃. Under acidic conditions similar to the stomach (pH 2, 37 ℃), it breaks down within minutes, releasing active paracetamol. Natural enzymes in the intestine and liver can also rapidly cleave the bond, enabling controlled and site-specific drug activation. Computer simulations confirm the proposed breakdown mechanism and support the experimental findings. Stability testing was performed under internationally recognised pharmaceutical guidelines (ICH, USP, FDA, EMA), showing predictable behaviour and acceptable impurity control. Formulation strategies such as protective coatings and temperature management suggest a projected shelf life of 2–3 years. Importantly, when the compound breaks down, it releases both paracetamol and a small amount of glucose. This creates a dual-action system that provides pain relief while also contributing mild energy support during illness. Paracetamol β-D-glucoside, therefore, represents a practical and scientifically validated approach to improving a widely used medicine.